Story perspectives

Health Canada Approves Leqembi: First Alzheimer's Drug in 20 Years

10/29/2025

47 3

Summary

Story summary

Health Canada approved lecanemab, sold as Leqembi, the first new Alzheimer's treatment in 20 years for early-stage disease.
Lecanemab targets beta-amyloid plaques and can delay disease progression by about five months.
Experts say benefits are modest and emphasize careful patient selection, noting that genetic testing is required to identify candidates.
Access may be limited by high costs and healthcare capacity, and patients may face additional monitoring requirements.

1 of 1

Story summary

Health Canada approved lecanemab, sold as Leqembi, the first new Alzheimer's treatment in 20 years for early-stage disease.
Lecanemab targets beta-amyloid plaques and can delay disease progression by about five months.
Experts say benefits are modest and emphasize careful patient selection, noting that genetic testing is required to identify candidates.
Access may be limited by high costs and healthcare capacity, and patients may face additional monitoring requirements.